- Romania, Bulgaria join borderless Schengen zone
- US Capitol riot fugitive seeks asylum in Canada
- Musk flummoxes internet with 'Kekius Maximus' persona
- US stocks slip as European markets ring out year with gains
- Olmo's Barcelona future in air over registration race
- Venezuela opposition urges protests against Maduro's inauguration
- Syria's de facto leader meets minority Christians
- Suriname ex-dictator Bouterse to be cremated on Saturday
- £1.5 mn reward offered after 'brazen' London gem raid
- Zimbabwe abolishes the death penalty
- Barcelona race against clock to register Olmo
- Arteta wants Arsenal to hammer away in title race
- Panama marks canal handover anniversary in shadow of Trump threat
- Gaza hospital chief held by Israel becomes face of crumbling healthcare
- Russian advances in Ukraine grew seven-fold in 2024, data shows
- US, European stock markets look to ring out year with gains
- US farmers fret over Trump's deportation plans
- BBC celebrates 100 years of 'poetic' shipping forecast
- West Ham's Bowen sidelined with foot fracture
- Global markets rode AI, interest rate roller coaster in 2024
- Ocalan: PKK chief held in solitary on Turkish prison island
- European stock markets end year with gains
- Yemen's Huthis a 'menace' for Israel despite weakened Iran: analysts
- Rooney exit extends managerial struggles for England's 'golden generation'
- Gaza healthcare nearing 'total collapse' due to Israeli strikes: UN
- German leaders hit back at Musk's support for far right
- Southgate won't be 'Sir' at home after knighthood
- Rooney leaves Plymouth after just seven months in charge
- Kyrgios needs 'miracle' after return from long injury layoff
- Raducanu pulls out of Australian Open warm-up with back problem
- Celebrated S.African contemporary dancer Dada Masilo dies aged 39
- Five talking points at the midway point of the Premier League season
- Angelina Jolie and Brad Pitt reach divorce settlement
- Djokovic, Sabalenka win season-openers but Kyrgios loses on return
- Taiwan says 2024 was hottest year on record
- China says shared Covid information 'without holding anything back'
- Kyrgios goes down fighting on return, Sabalenka wins season-opener
- Xi says China must apply 'more proactive' macroeconomic policies in 2025
- Gauff, Paolini on fire as USA, Italy surge into United Cup quarters
- Patients brave mental health desert in Mauritania
- Hart triple-double sparks Knicks to eighth straight NBA win
- Angelina Jolie and Brad Pitt reach divorce settlement: report
- Sabalenka opens season with 'tricky' win in Brisbane
- S. Korea starts releasing Jeju Air crash victims to families
- China's frigid northeast thrives on 'little potato' tourism boom
- Paolini on fire as Italy surge into United Cup quarter-finals
- Hart's triple double sparks Knicks to eighth straight NBA win
- Asian stocks dip as Santa snubs Wall Street
- World greets 2025 after sweltering year of Olympics, turmoil, and Trump
- Australia optimistic on Starc fitness for final India Test
Drew Weissman, Nobel-winning mRNA pioneer
Drew Weissman's decades of research into mRNA technology paved the way for Covid-19 vaccines, finally earning a Nobel prize for the physician-scientist.
The 64-year-old University of Pennsylvania immunologist, who won the Nobel Medicine Prize along with long-time collaborator Katalin Kariko on Monday, is far from done.
His next quests include, among others, developing a vaccine against all future coronaviruses.
"There have been three (coronavirus) pandemics or epidemics in the past 20 years," Weissman told AFP recently, referring to the original SARS virus, MERS and Covid-19.
"You have to assume there's going to be more, and our idea was that we could wait for the next coronavirus epidemic or pandemic, and then spend a year and a half making a vaccine. Or we could make one now."
- Twin breakthroughs-
The world is now aware of the elegance of the mRNA (messenger ribonucleic acid) vaccines, that deliver genetic instructions to cells telling them to recreate the spike protein of the coronavirus, in order to trigger effective antibodies when they encounter the real thing.
But back when Weissman teamed up with Kariko in the 1990s, the research was considered a scientific dead-end, and working with DNA was considered a more promising avenue.
"We started working together in 1998, and that was without much funding and without much in the way of publications," he said.
In 2005, the pair found a way to alter synthetic RNA to stop it from causing a massive inflammatory response found in animal experiments.
"Just before our paper was published, I said 'Our phones are going to ring off the hook,'" he recalls.
"We sat there staring at our phones for five years, and they never rang!"
With a second big breakthrough in 2015, they found a new way to deliver the particles safely and effectively to their target cells, using a fatty coating called "lipid nanoparticles."
Both developments are part of the Pfizer and Moderna Covid-19 vaccines today.
- Helping people -
Weissman grew up in Lexington, Massachusetts.
His father and mother, both since retired, were an engineer and dental hygienist, respectively.
"When I was five years old, I was diagnosed as a type-one diabetic, and back then it was testing urine and taking insulin shots a few times a day," he recalled, and this motivated him to pursue science.
He was educated at Brandeis University and completed an MD-Phd program in immunology at Boston University.
As a young fellow at the National Institutes of Health, he worked for several years in Anthony Fauci's lab on HIV research, before finally arriving at his long-time home Penn.
Weissman was a practicing doctor until a few years ago, and says it brings him great joy that his invention has helped save millions of lives.
"I'm a clinician scientist, my dream since starting college and medical school was to make something that helps people. I think I can say that I've done that. So I am incredibly happy," he said.
Beyond vaccines, mRNA technology is also being heralded for its potential across medicine.
Weissman's team is working on using RNA to develop a single-injection gene therapy to overcome the defect that causes sickle cell anemia, a genetic blood disease that 200,000 babies are born with in Africa every year.
Significant technical challenges remain to ensure the treatment is able to correctly edit genes and is safe, but the researchers are hopeful.
Bone marrow transplant, an expensive treatment with serious risks, is currently the only cure.
O.Johnson--AMWN